Comparison of no-reflow phenomenon after percutaneous coronary intervention for acute myocardial infarction between smokers and nonsmokers

Journal of Research in Medical Sciences

Volumn 19, Issue 11, 2014, Pages 1068-1073

  Shemirani, Hassan ^a   Tafti, Faezeh Dehghani ^a   Amirpour, Afshin ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cigarette smoking; No reflow phenomenon; Primary percutaneous coronary intervention; Thrombolysis in myocardial infarction flow

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ADULT; ANGIOGRAPHY; ARTICLE; BALLOON CATHETER; BLEEDING; BLOOD CLOT LYSIS; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; FEMALE; HEART ARRHYTHMIA; HEART REINFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NO REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; QUESTIONNAIRE; SMOKING; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THORAX PAIN;

EID: 84919832987     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J 2008;29:2909-45.
2. Taggart DP, Boyle R, de Belder MA, Fox KA. The 2010 ESC/EACTS guidelines on myocardial revascularisation. Heart 2011;97:445-6.
3. Gao RL. Current status and perspective of percutaneous coronary intervention in China. Chin Med J (Engl) 2006;119:531-2.
4. Gibson CM, Schömig A. Coronary and myocardial angiography: Angiographic assessment of both epicardial and myocardial perfusion. Circulation 2004;109:3096-105.
5. TIMI Study Group. Definitions used in TIMI trials. Available from: http://www.timi.org. [Last accessed on 2009 Jun 20].
6. Reffelmann T, Kloner RA. The no-reflow phenomenon: A basic mechanism of myocardial ischemia and reperfusion. Basic Res Cardiol 2006;101:359-72.
7. Ndrepepa G, Tiroch K, Keta D, Fusaro M, Seyfarth M, Pache J, et al. Predictive factors and impact of no reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction. Circ Cardiovasc Interv 2010;3:27-33.
8. Dong-bao L, Qi H, Zhi L, Shan W, Wei-ying J. Predictors and long-term prognosis of angiographic slow/no-reflow phenomenon during emergency percutaneous coronary intervention for STelevated acute myocardial infarction. Clin Cardiol 2010;33:E7-12.
9. Rezkalla SH, Dharmashankar KC, Abdalrahman IB, Kloner RA. Noreflow phenomenon following percutaneous coronary intervention for acute myocardial infarction: Incidence, outcome, and effect of pharmacologic therapy. J Interv Cardiol 2010;23: 429-36.
10. Jesel L, Morel O, Ohlmann P, Germain P, Faure A, Jahn C, et al. Role of pre-infarction angina and inflammatory status in the extent of microvascular obstruction detected by MRI in myocardial infarction patients treated by PCI. Int J Cardiol 2007;121:139-47.
11. Niccoli G, Giubilato S, Russo E, Spaziani C, Leo A, Porto I, et al. Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention. Eur Heart J 2008;29:1843-50.
12. Jeong YH, Kim WJ, Park DW, Choi BR, Lee SW, Kim YH, et al. Serum B-type natriuretic peptide on admission can predict the ‘no-reflow’ phenomenon after primary drug-eluting stent implantation for ST-segment elevation myocardial infarction. Int J Cardiol 2010;141:175-81.
13. Eitel I, Nowak M, Stehl C, Adams V, Fuernau G, Hildebrand L, et al. Endothelin-1 release in acute myocardial infarction as a predictor of long-term prognosis and no-reflow assessed by contrast-enhanced magnetic resonance imaging. Am Heart J 2010;159:882-90.
14. Dominguez-Rodriguez A, Abreu-Gonzalez P, Jimenez-Sosa A, Avanzas P, Bosa-Ojeda F, Kaski JC. Usefulness of intraplatelet melatonin levels to predict angiographic no-reflow after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. Am J Cardiol 2010;106:1540-4.
15. Higashikuni Y, Tanabe K, Tanimoto S, Aoki J, Yamamoto H, Nakazawa G, et al. Impact of culprit plaque composition on the no-reflow phenomenon in patients with acute coronary syndrome: An intravascular ultrasound radiofrequency analysis. Circ J 2008;72:1235-41.
16. Hong YJ, Jeong MH, Choi YH, Ko JS, Lee MG, Kang WY, et al. Impact of plaque components on no-reflow phenomenon after stent deployment in patients with acute coronary syndrome: A virtual histology-intravascular ultrasound analysis. Eur Heart J 2011;32:2059-66.
17. Kirma C, Izgi A, Dundar C, Tanalp AC, Oduncu V, Aung SM, etal. Clinical and procedural predictors of no-reflow phenomenon after primary percutaneous coronary interventions: Experience at a single center. Circ J 2008;72:716-21.
18. Ndrepepa G, Mehilli J, Schulz S, Iijima R, Keta D, Byrne RA, et al. Prognostic significance of epicardial blood flow before and after percutaneous coronary intervention in patients with acute coronary syndromes. J Am Coll Cardiol 2008;52:512-7.
19. Weisz G, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, et al. Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction — the smoker’s paradox revisited. Am Heart J 2005;150:358-64.
20. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Circulation 2012;126:2020-35.
21. Chen Z, Boreham J. Smoking and cardiovascular disease. Semin Vasc Med 2002;2:243-52.
22. Teo KK, Ounpuu S, Hawken S, Pandey MR, Valentin V, Hunt D, et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: A case-control study. Lancet 2006;368:647-58.
23. Sherif MA, Nienaber CA, Toelg R, Abdel-Wahab M, GeistV, Schneider S, et al. Impact of smoking on the outcome of patients treated with drug-eluting stents: 1-year results from the prospective multicentre German Drug-Eluting Stent Registry (DES.DE). Clin Res Cardiol 2011;100:413-23.
24. Sukiennik A, Kozinski M, Debska-Kozinska K, Kubica A, Grabczewska Z, Kubica J. Smokers versus non-smokers undergoing percutaneous transluminal coronary angioplasty: The impact of clinical and procedural characteristics on in-hospital mortality. Cardiol J 2007;14:482-92.
25. Iwakura K, Ito H, Kawano S, Shintani Y, Yamamoto K, Kato A, et al. Predictive factors for development of the no-reflow phenomenon in patients with reperfused anterior wall acute myocardial infarction. J Am Coll Cardiol 2001;38:472-7.
26. Ndrepepa G, Tiroch K, Fusaro M, Keta D, Seyfarth M, Byrne RA, et al 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol 2010;55: 2383-9.
27. Niccoli G, Lanza GA, Spaziani C, Altamura L, Romagnoli E, Leone AM, et al. Baseline systemic inflammatory status and no-reflow phenomenon after percutaneous coronary angioplasty for acute myocardial infarction. Int J Cardiol 2007;1 17:306-11.
28. Albertal M, Cura F, Escudero AG, Thierer J, Trivi M, Padilla LT, et al. Mechanism involved in the paradoxical effects of active smoking following primary angioplasty: A subanalysis of the protection of distal embolization in high-risk patients with acute myocardial infarction trial. J Cardiovasc Med (Hagerstown) 2008;9:810-2.
29. Desai NR, Mega JL, Jiang S, Cannon CP, Sabatine MS. Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol 2009;53:1273-8.
30. Sorajja P, Gersh BJ, Costantini C, McLaughlin MG, Zimetbaum P, Cox DA, et al. Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction. Eur Heart J 2005;26: 667-74.